| Polycomb-mediated silencing in neuroendocrine prostate cancer PL Clermont, D Lin, F Crea, R Wu, H Xue, Y Wang, KL Thu, WL Lam, ... Clinical epigenetics 7, 1-13, 2015 | 143 | 2015 |
| The non-coding transcriptome as a dynamic regulator of cancer metastasis F Crea, PL Clermont, A Parolia, Y Wang, CD Helgason Cancer and metastasis reviews 33, 1-16, 2014 | 103 | 2014 |
| Elevated expression of the centromere protein‐A (CENP‐A)‐encoding gene as a prognostic and predictive biomarker in human cancers X Sun, PL Clermont, W Jiao, CD Helgason, PW Gout, Y Wang, S Qu International journal of cancer 139 (4), 899-907, 2016 | 96 | 2016 |
| Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role PL Clermont, L Sun, F Crea, KL Thu, A Zhang, A Parolia, WL Lam, ... British journal of cancer 111 (8), 1663-1672, 2014 | 94 | 2014 |
| The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo A Parolia, F Crea, H Xue, Y Wang, F Mo, VR Ramnarine, HH Liu, D Lin, ... Molecular cancer 14, 1-7, 2015 | 90 | 2015 |
| Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer PL Clermont, F Crea, YT Chiang, D Lin, A Zhang, JZL Wang, A Parolia, ... Clinical epigenetics 8, 1-14, 2016 | 83 | 2016 |
| CUX1 transcription factor is required for optimal ATM/ATR-mediated responses to DNA damage C Vadnais, S Davoudi, M Afshin, R Harada, R Dudley, PL Clermont, ... Nucleic acids research 40 (10), 4483-4495, 2012 | 82 | 2012 |
| EZH2 inhibition: a promising strategy to prevent cancer immune editing N Kang, M Eccleston, PL Clermont, M Latarani, DK Male, Y Wang, F Crea Epigenomics 12 (16), 1457-1476, 2020 | 47 | 2020 |
| Long-range transcriptional regulation by the p110 CUX1 homeodomain protein on theENCODE array C Vadnais, AA Awan, R Harada, PL Clermont, L Leduy, G Bérubé, ... BMC genomics 14, 1-17, 2013 | 32 | 2013 |
| Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines PL Clermont, X Ci, H Pandha, Y Wang, F Crea International Journal of Endocrine Oncology 6 (2), IJE20, 2019 | 29 | 2019 |
| Polycomb genes are associated with response to imatinib in chronic myeloid leukemia F Crea, A Di Paolo, HH Liu, M Polillo, PL Clermont, F Guerrini, E Ciabatti, ... Epigenomics 7 (5), 757-765, 2015 | 25 | 2015 |
| DNA methylation at enhancer regions: Novel avenues for epigenetic biomarker development PL Clermont, A Parolia, HH Liu, CD Helgason Front Biosci (Landmark Ed) 21, 430-446, 2016 | 22 | 2016 |
| Histone modifications, stem cells and prostate cancer F Crea, PL Clermont, A Mai, C D Helgason Current pharmaceutical design 20 (11), 1687-1697, 2014 | 17 | 2014 |
| Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer S Qu, X Ci, H Xue, X Dong, J Hao, D Lin, PL Clermont, R Wu, CC Collins, ... British Journal of Cancer 118 (6), 802-812, 2018 | 16 | 2018 |
| Development of a transcriptional amplification system based on the PEG3 promoter to target androgen receptor-positive and-negative prostate cancer cells P Jain, PL Clermont, F Desmeules, A Zoubeidi, B Neveu, F Pouliot International journal of molecular sciences 20 (1), 216, 2019 | 6 | 2019 |
| Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer PL Clermont, L Fornaro, F Crea Epigenomics 9 (10), 1329-1335, 2017 | 6 | 2017 |
| Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer PL Clermont Epigenomics 15 (2), 75-87, 2023 | 1 | 2023 |
| Trithorax Genes in Prostate Cancer PL Clermont, F Crea, CD Helgason Advances in Prostate Cancer, 2013 | 1 | 2013 |
| Identification of the Polycomb protein CBX2 as a potential drug target in advanced prostate cancer and beyond PL Clermont University of British Columbia, 2015 | | 2015 |
